Developing a CD71-Targeting Probody[™] Drug Conjugate (PDC) for Activity in Multiple Solid Tumor and Lymphoma Models and for Tolerability in Non-human Primates

Shweta Singh¹, Laura Serwer¹, Niharika Chauhan², Amy DuPage¹, Michael Krimm¹, Ken Wong¹, Fric Ureno¹, Adam Miller¹, Sarah Patrick¹, Shanti Duvur¹, Fritz Buchanan², Matthew Ravn², Rob Leanna², Ilaria Badagnani³, Tracy Henriques², Shouchun Liu¹, Luc Desnoyers¹, Claus Krebber¹, Sridhar Viswanathan¹, Jennifer Richardson¹, Susan Morgan-Lappe² and W. Michael Kavanaugh¹ ¹CytomX Therapeutics, Inc., South San Francisco, CA; ²AbbVie, North Chicago, IL, ³Former Abbvie Employee

ABSTRACT

Probody™ therapeutics are antibody prodrugs designed to remain largely inactive until proteolytically activated in the tumor microenvironment (TME), potentially enabling the safer targeting of antigens that are highly expressed in both tumor and normal tissue. CD71 (transferrin receptor) is an example of an ideal Probody Drug Conjugate (PDC) target not only because it efficiently internalizes and can deliver a cytotoxic payload intracellularly, but also because it is expressed at high levels both in many different tumor types as well as in dividing normal cells. We have previously demonstrated that while an anti-CD71 antibody drug conjugate (ADC) is highly toxic, a CD71-targeting PDC is both efficacious in mouse tumor models and well tolerated in non-human primates.

Two key components of a Probody therapeutic prodomain that reduce its binding to normal tissue and allow for its tumor-specific activation are 1) a mask that reduces the ability of the antibody binding site to interact with target antigen and 2) a protease-activatable substrate that is cleaved in the TME resulting in removal of the mask. Here, we demonstrate how modulating mask strength and substrate cleavability can impact efficacy and safety of a CD71targeting PDC in preclinical models. Through this process, we have selected a lead molecule, CX-2029, for further development. CX-2029 is a CD71 targeting PDC conjugated to vcMMAE with a Drug to Probody Ratio (DPR) of 2, achieved by purification.


At comparable dose levels, a more strongly masked PDC, CX-2018, was less efficacious in a mouse xenograft tumor model compared to PDC CX-2016, which has a weaker mask, demonstrating that mask strength affects anti-tumor activity. Further, PDC CX-2019, which has the same mask but a less cleavable substrate than CX-2016, was similarly efficacious in a mouse xenograft tumor model, demonstrating that both substrates are sufficiently cleaved in the TME to activate the PDCs. However, CX-2019 was better tolerated in NHP at 6 mg/kg than CX-2016, suggesting that the less cleavable substrate in CX-2019 leads to a better therapeutic index. Using a LC/MS/MS method, we showed lower levels of circulating activated CX-2019 compared with circulating activated CX-2016, which is consistent with CX-2019's improved tolerability. Lead CX-2029 contains the same mask and substrate as CX-2019 but differs in having a DPR of 2 versus ~3 for CX-2019. Up to 6 mg/kg of CX-2029 as a single dose produced complete regressions and durable responses in mouse xenograft tumor models encompassing multiple indications, and was tolerated in monkeys at doses of up to 12 mg/kg.

These data demonstrate that, in preclinical models, changes in mask strength and substrate cleavability can enhance the efficacy and tolerability of Probody Therapeutics and have the potential to enable the safe and effective targeting of highly expressed tumor antigens like CD-71. CX-2029 is currently under development, with an IND filing expected in

CD71 BACKGROUND

- CD71, TfR, TRFC (transferrin receptor) is a transmembrane glycoprotein that exists as a 180 kDa homodimer whose function is to primarily bind transferrin
- The receptor is continuously re-cycled through endocytosis
- CD71 is ubiquitously expressed on dividing cells
- CD71 is highly expressed in almost all primary and metastatic cancers evaluated

CD71 is Highly Expressed in Many Metastatic Cancers






Figure 1: Panel of IHC images represent strong staining in the stated indications. Graph represents 2/3+ staining at metastatic sites in patient tumors.

PROBODY is a trademark of CytomX Therapeutics, Inc

Potent in vitro Cytotoxicity of the parental CD71 ADC in Multiple Tumor Cell Types




Figure 2: EC₅₀ values represented for 5 day cell death assay across multiple cell lines where each point represents one cell line. A fully activated CD71 PDC shows the same activity as the ADC.

	 •
•	C)
•	W
•	C
•	Pr

Te
Art
CX-2





Figure 4: Single dose of CX-2018 and CX-2016, at 3mpk in HT-29 cell line derived xenograft (CDX). The lower affinity mask PDC gives complete regressions and the high affinity mask results in marginal TGI after a single dose. Both CX-2018 and CX-2016 have the same, more cleavable, substrate. Same result were observed with a less cleavable substrate (data not shown).






Table 2: Cynomolgus monkeys were treated IV, scheduled q3wx2, with CD71 PDCs (n=2). The same, lower affinity, mask with different substrates or different DPR format or an E2 containing ADC (n=1) were dosed. Only one dose was tolerated for CX-2016 and only one dose was administered for the ADC. Stability of Probody Tx was measured using an LC/ MS/MS method to monitor intact vs. total Pb (visit poster B103) ^baseline neutrophil count ≥1000/ul *Lowest measured value after 1st dose

Article/ or DAR	Dose mpk	*Body weight loss	*Average ^Neutrophil count +/- SD (per ul)	Relative stability of Probody Tx in circulation	Tolerability
-2016 PR~3	6 mpk	~10%	98 ± 60	Lower	Not tolerated
-2019 PR~3	6 mpk	~8%	290 ± 290	Higher	Tolerated
-2029 PR~2	12 mpk	0%	180 ± 210	Higher	Tolerated
-2030 \R~2	2 mpk	~8%	70	NA	Not tolerated

• CD71-ADC demonstrates lack of tolerability within 8 days of a single dose of 2 mpk of DAR 2 purified ADC

• CX-2019 is better tolerated and is more stable in circulation in cyno than CX-2016

CX-2029 demonstrates improved tolerability when administered at a higher dose compared to CX-2019

- The lower affinity mask significantly improved efficacy in mouse tumor models
- The less cleavable substrate resulted in improved tolerability in NHP and improved stability of circulating Probody therapeutics without compromising efficacy in mouse tumor models
- The lower DPR 2 purified PDC resulted in improved tolerability in NHP whilst maintaining potent activity in mouse tumor models

B116

TypeCell line or Patient derived xenograftRegressions or StasisGrowth InhibitionNo responseTable 3. More than 4 or PDX models were agnostically run with prior evaluation of C expression. No correct between CD71 expr and CDX1CDX1III	e tested; n no CD71 elation ression
ricCDX1anagnostically run with prior evaluation of CanCDX21prior evaluation of C1CDX11expression. No correct between CD71 expr and efficacy was observed	CD71 elation ression
anCDX21prior evaluation of C1CDX11expression. No correctateCDX1between CD71 expreliomaCDX11and efficacy was observed	CD71 elation ression
1CDX1expression. No correlateateCDX1between CD71 expreliomaCDX11and efficacy was obstance	elation ression
ateCDX1between CD71 expreliomaCDX1and efficacy was observed	ression
elioma CDX 1 and efficacy was ob	
	301 VCU
ctal CDX 2 1 in these models. PE	
an CDX 2 1 models were selected	ed for
CDX 3 1 high CD71 expression	
gealPDX2Overall, >90% of m	odels
CDX 3 1 responded, resulting	•
PDX 2 1 1 regressions/ stasis of	
CDX 3 2 growth inhibition. P	
st PDX 3 activation status unk	nown in
CL PDX 4 1 these models.	variad:
PDX2Dosing schedules v q2wx2, q1wx2 or sir	
CDX 17 (65%) 8 (31%) 1 (4%)	IGIE
$PDX 13 (81\%) 2 (13\%) 1 (6\%) dose at \le 6 mpk.$	

Probody Therapeutics have the potential to enable the safe and effective targeting of highly expressed tumor antigens, regardless of expression on normal tissue, like CD71, thus expanding the utility of ADCs

We have developed an efficacious and well tolerated PDC targeting CD71, CX-2029, by modifying mask, substrate and drug Probody ratio (DPR) properties

- CX-2029 was better tolerated in monkeys than the parental ADC with matching DAR, which was not tolerated after a single dose at 2 mg/kg
- CX-2029 is currently under development with an IND filing expected in 2018